TrialNCT06369259
Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in Patients With Unresectable, Anti-EGFR-Refractory Advanced Colorectal Cancer
- Status
- RECRUITING
- Phase
- PHASE2
- Last update posted
- 09/04/2026
- Start
- 02/24/2025
- Sponsor
- M.D. Anderson Cancer Center
- Specialties
- oncology
Conditions: Advanced Colorectal Cancer
Brief summary
To learn if avutometinib in combination with defactinib and cetuximab can help to control unresectable, anti-EGFR-refractory, advanced colorectal cancer.
Protocol documents and results are not hosted here. Verify every detail on ClinicalTrials.gov.